---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-081162"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-07-19T23:59:59+00:00"
generated_at: "2026-05-31T18:56:43.975822+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq warns Brainstorm Cell Therapeutics of MVLS deficiency; 180 days to comply

## Summary
- Received Nasdaq deficiency notice on July 18, 2024 for MVLS below $35M minimum.
- Company has until January 14, 2025 to regain compliance by closing at $35M or more for 10 consecutive business days.
- If not compliant by deadline, Nasdaq may delist BCLI common stock; company may appeal.
- No immediate impact on trading; BCLI continues to trade on Nasdaq Capital Market.
- Company intends to monitor and take reasonable measures to regain compliance.

## SEC filing metadata
- accession: 0001104659-24-081162
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-07-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924081162/0001104659-24-081162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924081162/tm2419839d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-081162
- JSON: https://secwatch.observer/filing/0001104659-24-081162.json
- Plain text: https://secwatch.observer/filing/0001104659-24-081162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.